SCIEX, a global leader in life science analytical technologies, announced that Aarhus University Hospital in Denmark has invested in SCIEX QTRAP® 6500 technology to develop novel mass spectrometry-based assays for clinical research laboratories.
Scientists at the hospital’s Department of Clinical Biochemistry are using the QTRAP 6500 LC-MS/MS system for advanced clinical research, due to its exceptional sensitivity and selectivity, which are essential for compound detection at trace levels in complex biological matrices. The SCIEX QTRAP 6500 LC-MS/MS system with Ion Drive™ Technology increases the number of ions produced, and at the same time improves the way ions are transmitted and detected, optimising the limits of quantitation.
LC-MS/MS based methods are highly sensitive and achieve extremely low limits of detection, thus overcoming the performance of some immunoassays limited by interference issues. “The advantages of using the QTRAP 6500 for our research are that it has extremely good selectivity and sensitivity; it produces exceptionally reliable results as well as providing the highest uptime,” said Carsten Schriver Højskov, Aarhus University Hospital. The laboratory now has two SCIEX 5500 systems, four SCIEX QTRAP 6500 systems, and a TripleTOF® 5600 instrument.
“We have always had a good experience with SCIEX instruments and we have received excellent service from the company through collaboration with their application specialists,” added Carsten Schriver Højskov.
“The research excellence achieved by our customers is a true indicator of the quality of our instruments and the strength of our application specialists and global support teams,” said Chris Radloff, Global Vice President & General Manager of the LC-MS Business at SCIEX. “We listen carefully to what our customers need to support their applications, and SCIEX innovates to exceed those needs.”
Learn more about the SCIEX QTRAP 6500 System.
